Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-PD
NCT06913647Phase 2Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canagliflozin in end stage renal disease (ESRD) (3 arms), sponsored by McGill University Health Centre. Primary endpoint: Change in D4/D0 at 10 weeks. Started Feb 2026; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT06913647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913647.